|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
MarketWatch
4 hrs ago
Comment
Arena Pharmaceuticals shares rocketed 75% to $6.42 early Friday, the day after an advisory panel of the U.S. Food and Drug Administration voted to recommend agency approval for Arena's diet pill lorcaserin. A final decision is expected by June...
Globe Newswire
May 7
Comment
MOUNTAIN VIEW, Calif., May 7, 2012 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the first quarter
Globe Newswire
May 4
Comment
MOUNTAIN VIEW, Calif., May 4, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investor conferences during the month of May. The
Marketwire
May 2
Comment
NEW YORK, NY -- (Marketwire) -- 05/02/12 -- A new study shows that medical costs as a result of obesity is nearly double that of previous estimates, and even higher than those caused by smoking. As a result Biotech companies are looking to cash in on
Globe Newswire
May 1
Comment
MOUNTAIN VIEW, Calif., May 1, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the first quarter ended March 31, 2012 after the NASDAQ Market closes on Monday, May 7, 2012. The company will
FiercePharma
Apr 30
Comment
Vivus ($VVUS) finally won an approval from FDA: The agency has blessed its erectile dysfunction treatment, Stendra. Now, Vivus has to figure out how to sell it--or find a buyer for the whole company. Report
FierceBiotech
Apr 27
Comment
The FDA issued word this afternoon that it had stamped its OK on Stendra (avanafil), an erectile dysfunction treatment designed to spur a quicker response for men. The drug will enter a crowded field of rival and better known treatments in a mass...
Benzinga
Apr 27
Comment
VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a...
StreetInsider.com
Apr 27
Comment
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
VIVUS, Inc. (Nasdaq: VVUS) high of $26.18. VIVUS popped to its new 52-week high Friday following reports that...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
